Funding for this research was provided by:
Cancer Research UK (A26941))
Medical Research Council (MR/T028254/1, MR/T028254/1)
Biotechnology and Biological Sciences Research Council (BB/R017956/1, BB/T018275/1)
National Health and Medical Research Council (1117017)
Australian Research Council (CE140100011)
Received: 13 October 2020
Accepted: 29 November 2020
First Online: 4 January 2021
Ethics approval and consent to participate
: Not applicable.
: Consent for publication has been obtained from all authors.
: JMM is an advisor to Sapience Therapeutics. The authors declare no other competing interests.